

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

January 22, 2018

To,

The Manager **Listing Operations**

BSE Limited

Sir Phiroze Jeejeebhoy Towers

Dalal Street, Fort Mumbai - 400 001

Scrip Code: 537291

ISIN: INE448G01010

To,

The Manager

Listing Department

National Stock Exchange of India Limited

Exchange Plaza,

Bandra Kurla Complex

Bandra (E), Mumbai-400051

Scrip Code: NATHBIOGEN

ISIN: INE448G01010

Dear Sir.

Sub: Intimation of the outcome of the QIP Committee meeting of Nath Bio-Genes (India) Limited (the 'Company') held today in connection with the Qualified Institutions Placement ('QIP')

This is to inform you that subsequent to the approval accorded by the Board of Directors of the Company, at its meeting held on December 8, 2017 and the approval of the shareholders of the Company by way of a special resolution on January 5, 2018 for the QIP and QIP Committee at its meeting held on January 9, 2018 authorising the opening of the QIP on January 22, 2018 and approving the floor price for the QIP, the QIP Committee of the Company today i.e. January 22, 2018 has, inter alia passed the following resolutions:

- Approving the preliminary placement document dated January 22, 2018 in connection with the QIP, (the "Preliminary Placement Document"); and
- Confirming the opening of the QIP on January 22, 2018.

The Meeting of the Committee commenced at 2.00 p.m. and concluded at 2.30 p.m.

Further, as intimated earlier the 'Relevant Date' for this purpose, in terms of Regulation 81(c) (i) of the SEBI ICDR Regulations, is January 9, 2018 and accordingly the floor price in respect of the aforesaid QIP, based on the pricing formula as prescribed under Regulation 85(1) of the SEBI ICDR Regulations is ₹ 468.69 per Equity Share. Pursuant to Regulation 85 of the SEBI ICDR Regulations, and further to the shareholders resolution dated January 5, 2018, the Company may offer a discount of not more than 5% on the floor price so calculated for the QIP.

The Exchanges are requested to take the above on record and acknowledge the receipt of the same.

Capitalized terms used herein shall have the respective meaning assigned to them in the Preliminary Placement Document unless specifically defined herein.

Yours truly,

For Nath Bio-Genes (India) Limited

Devinder Khurana Chief Financial Officer

Nath House, Nath Road, Aurangabad - 431005 (MS) Tel: 0240-2376314/5/6/7

Email: info@nathseeds.com www.nathbiogenes.com

1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel: 022-22871001, 22875653/4/5